2013-02-22 12:39:40 -

Biofrontera AG /
Misc. matters  /
Ad hoc: Biofrontera AG: Ameluz® Cooperation Agreement for Slovenia with PHA 
FARMED Consultancy s.p. 
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

Leverkusen, 22 February 2013 - Biofrontera Pharma GmbH, a fully-owned subsidiary
of Biofrontera AG, has today signed an exclusive agreement with PHA Farmed s.p.,
Ljubljana,  for  the  marketing  of  Ameluz(®)  in  Slovenia.  In December 2011
Ameluz(®)  received a  centralized European  approval as  prescription medicinal
product  for the first-line treatment of  mild and moderate actinic keratosis in
the face and on the scalp.

To  assure the efficient and successful penetration of the Slovenian market with
Ameluz(®)    PHA Farmed  provides fully  integrated expert  solutions as strategic
partnership at all stages of the pharmaceutical business process.

PHA Farmed will support Biofrontera in the marketing of Ameluz(®) in Slovenia, a
market  in which German  or English labeling  on tubes and  packages is accepted
upon  application. Biofrontera will  thus be able  to sell Ameluz(®) without the
need  for separate manufacturing to a local wholesaler for further distribution.
All activities and costs related to marketing and sales, local reimbursement and
pricing  negotiations,  and  local  pharmacovigilance  will  be  taken on by PHA
Farmed.  In return, PHA Farmed will receive 40% of the revenues that Biofrontera
achieves in this Territory with Ameluz(®).

Ameluz(®)  is used  in the  treatment of  actinic keratosis,  a superficial skin
cancer,  by photodynamic therapy (PDT). The  treatment combines Ameluz(®) with a
strong   red   light  illumination,  provided  f.i.  through  Biofrontera's  BF-
RhodoLED(®)  lamp, the marketing of which is also ruled by the agreement between
the two companies.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

Contact:
Anke zur Mühlen
Biofrontera AG
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290
E-mail: a.zurmuehlen@biofrontera.com




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1680388]